IQVIA Holdings Inc. (IQV)Healthcare | Diagnostics & Research | Durham, United States | NYSE
207.55 USD
-0.30
(-0.144%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:21 a.m. EDT
The momentum is undeniable, with the stock surging nearly 25% in just two weeks to trade well above its 50-day average. Fundamentally, the company offers a compelling re-rating story with forward earnings growth driving a compressed valuation relative to trailing metrics, and analysts see roughly 10% upside to their mean target. However, the balance sheet remains a liability with high leverage and a current ratio below 1.0, which caps the long-term rating despite strong ROE and revenue growth. There is no dividend history available to provide income or cushion against volatility. While the statistical forecast model is currently neutral due to low confidence, the price action and options flow suggest a strong short-term catalyst is in place, making this a high-conviction entry for the near term, though investors should monitor the debt load closely for the long haul. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.108363 |
| AutoARIMA | 0.108366 |
| MSTL | 0.111291 |
| AutoTheta | 0.111836 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 3.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.885 |
| Excess Kurtosis | 0.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 255.426 |
| Revenue per Share | 97.792 |
| Market Cap | 34,640,097,280 |
| Trailing P/E | 25.85 |
| Forward P/E | 14.65 |
| Beta | 1.20 |
| Profit Margins | 8.33% |
| Website | https://www.iqvia.com |
As of July 11, 2026, 4:21 a.m. EDT: Speculators are positioning for a significant rebound with heavy call interest at strikes above 230 for 2027, while put buyers establish a floor around 150-185 for mid-2026. Elevated implied volatility reflects uncertainty surrounding the recent price surge and earnings expectations, though net positioning leans bullish on the longer timeline.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.29800785 |
| Address1 | 2,400 Ellis Road |
| All Time High | 285.61 |
| All Time Low | 40.1 |
| Ask | 0.0 |
| Ask Size | 200 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,326,910 |
| Average Daily Volume3 Month | 1,657,103 |
| Average Volume | 1,657,103 |
| Average Volume10Days | 1,326,910 |
| Beta | 1.2 |
| Bid | 200.01 |
| Bid Size | 200 |
| Board Risk | 6 |
| Book Value | 37.274 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 207.55 |
| Current Ratio | 0.747 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 212.36 |
| Day Low | 207.015 |
| Debt To Equity | 255.426 |
| Display Name | IQVIA |
| Earnings Call Timestamp End | 1,785,268,800 |
| Earnings Call Timestamp Start | 1,785,268,800 |
| Earnings Growth | 0.15 |
| Earnings Quarterly Growth | 0.1 |
| Earnings Timestamp | 1,785,241,800 |
| Earnings Timestamp End | 1,785,241,800 |
| Earnings Timestamp Start | 1,785,241,800 |
| Ebitda | 3,000,999,936 |
| Ebitda Margins | 0.18044001 |
| Enterprise To Ebitda | 16.289 |
| Enterprise To Revenue | 2.939 |
| Enterprise Value | 48,882,094,080 |
| Eps Current Year | 12.80134 |
| Eps Forward | 14.16987 |
| Eps Trailing Twelve Months | 8.03 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 180.268 |
| Fifty Day Average Change | 27.281998 |
| Fifty Day Average Change Percent | 0.15134132 |
| Fifty Two Week Change Percent | 29.800785 |
| Fifty Two Week High | 247.05 |
| Fifty Two Week High Change | -39.5 |
| Fifty Two Week High Change Percent | -0.15988666 |
| Fifty Two Week Low | 154.5 |
| Fifty Two Week Low Change | 53.050003 |
| Fifty Two Week Low Change Percent | 0.34336573 |
| Fifty Two Week Range | 154.5 - 247.05 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,368,106,200,000 |
| Float Shares | 158,549,993 |
| Forward Eps | 14.16987 |
| Forward P E | 14.647276 |
| Free Cashflow | 2,156,750,080 |
| Full Exchange Name | NYSE |
| Full Time Employees | 93,000 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.32991 |
| Gross Profits | 5,487,000,064 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01079 |
| Held Percent Institutions | 1.04054 |
| Implied Shares Outstanding | 166,900,000 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina. |
| Long Name | IQVIA Holdings Inc. |
| Market | us_market |
| Market Cap | 34,640,097,280 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_137473239 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 1,384,999,936 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 34,690,165,000 |
| Number Of Analyst Opinions | 19 |
| Open | 207.85 |
| Operating Cashflow | 2,704,000,000 |
| Operating Margins | 0.13611001 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.84 |
| Phone | 919 998 2000 |
| Pre Market Change | -2.3600006 |
| Pre Market Change Percent | -1.1370757 |
| Pre Market Price | 205.19 |
| Pre Market Time | 1,784,016,938 |
| Previous Close | 207.85 |
| Price Eps Current Year | 16.213146 |
| Price Hint | 2 |
| Price To Book | 5.568225 |
| Price To Sales Trailing12 Months | 2.082738 |
| Profit Margins | 0.08327 |
| Quick Ratio | 0.658 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.45455 |
| Region | US |
| Regular Market Change | -0.300003 |
| Regular Market Change Percent | -0.144336 |
| Regular Market Day High | 212.36 |
| Regular Market Day Low | 207.015 |
| Regular Market Day Range | 207.015 - 212.36 |
| Regular Market Open | 207.85 |
| Regular Market Previous Close | 207.85 |
| Regular Market Price | 207.55 |
| Regular Market Time | 1,783,972,803 |
| Regular Market Volume | 1,307,688 |
| Return On Assets | 0.051269997 |
| Return On Equity | 0.22490999 |
| Revenue Growth | 0.084 |
| Revenue Per Share | 97.792 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 166,900,000 |
| Shares Percent Shares Out | 0.0298 |
| Shares Short | 4,977,929 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,893,728 |
| Short Name | IQVIA Holdings, Inc. |
| Short Percent Of Float | 0.0345 |
| Short Ratio | 3.06 |
| Source Interval | 15 |
| State | NC |
| Symbol | IQV |
| Target High Price | 284.0 |
| Target Low Price | 200.0 |
| Target Mean Price | 230.42105 |
| Target Median Price | 225.0 |
| Total Cash | 2,103,000,064 |
| Total Cash Per Share | 12.6 |
| Total Debt | 16,216,999,936 |
| Total Revenue | 16,632,000,512 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 8.03 |
| Trailing P E | 25.846827 |
| Trailing Peg Ratio | 0.8377 |
| Triggerable | 1 |
| Two Hundred Day Average | 195.885 |
| Two Hundred Day Average Change | 11.665009 |
| Two Hundred Day Average Change Percent | 0.059550293 |
| Type Disp | Equity |
| Volume | 1,307,688 |
| Website | https://www.iqvia.com |
| Zip | 27,703 |